Evidence map›Paper›PMID 23728339›Full record

ArticleOncogene2014

miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.

C-J Kao, A Martiniez, X-B Shi, J Yang, C P Evans, A Dobi, R W deVere White, H-J Kung

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04188275 (CIRCULATING MICRO-RNA), which is not on this map. Cited by 87 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04188275 unknown statusnot on this mapstarted 2018, after this paper: background citation

CIRCULATING MICRO-RNA (miRNA) AND AR-V7 MUTATIONAL STATUS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): PRIMERA+ STUDY (PROSTATE CANCER INNOVATING MARKERS OF EXPECTED RESPONSE TO AGONIST LHRH+ ANDROGEN RECEPTOR INHIBITION

TypeobservationalSponsorAzienda Ospedaliero-Universitaria CareggiRan2018 to 2022Enrolled46ConditionsD011471, D064129, D035683, D009360ArmsPeriodic ARV7 and miRNA evaluation
3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 1 synthesis or guideline pooled it, 145 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Androgen Receptor-Related Non-coding RNAs in Prostate Cancer.Frontiers in cell and developmental biology · 2021
    Review
  18. Article
  19. Review
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

C-J KaoDepartment of Biochemistry and Molecular Medicine, University of California-Davis, Davis, CA, USA.
A MartiniezDepartment of Biochemistry and Molecular Medicine, University of California-Davis, Davis, CA, USA.
X-B ShiDepartment of Urology, University of California-Davis, Sacramento, CA, USA.
J YangDepartment of Urology, University of California-Davis, Sacramento, CA, USA.
C P EvansDepartment of Urology, University of California-Davis, Sacramento, CA, USA.
A DobiCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Rockville, MD, USA.
R W deVere WhiteDepartment of Urology, University of California-Davis, Sacramento, CA, USA.
H-J Kung1] Department of Biochemistry and Molecular Medicine, University of California-Davis, Davis, CA, USA [2] Institute of Molecular and Genomic Medicine, National Health Research Institutes, Maioli, Taiwan [3] Translational Medicine and Integrated Lab, Taipei Medical University, Taipei, Taiwan.
University of California, Davis · USTaipei Medical University · TWUniformed Services University of the Health Sciences · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
Tyrosine Kinases and Prostate CancerR01CA165263 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KUNG, HSING-JIEN · 2012 to 2016
$1.7M
Androgen Signaling and Coactivator Regulation in PCAR01CA150197 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KUNG, HSING-JIEN · 2010 to 2014
$1.7M
NCI NIH HHS CA150197NCI NIH HHS CA165263NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA150197NCI NIH HHS R01 CA165263
6 · The paper itself

Abstract

Src tyrosine kinase (Src) is implicated in the development of bone metastasis and castration resistance of prostate cancer. Src inhibitors are currently being tested in clinical trials for such diseases. Understanding the molecular and cellular actions of Src inhibitors holds the key to future improvement of this line of therapy. Here we describe the microRNA expression profiles modulated by two Src inhibitors and demonstrate that the miR-30 family members are the most prominently induced species. Consistent with its tumor suppressor role, miR-30 is downmodulated by oncogenic signals such as epidermal growth factor (EGF) and hepatocyte growth factor, and is generally underexpressed in prostate cancer specimens. A number of epithelial-to-mesenchymal transition (EMT)-associated genes are predicted targets of miR-30. Among these genes the Ets-related gene (ERG) is the most frequently overexpressed oncogene in prostate cancer activated by genomic fusion events between promoter upstream sequences of the TMPRSS2 and coding sequences of ERG. We showed by ERG 3' untranslated region reporter and mutagenesis assays that ERG is a direct target of miR-30. Overexpression of miR-30 in prostate cancer cells suppresses EMT phenotypes and inhibits cell migration and invasion. It also inhibits the in vitro and in vivo growth of VCaP cells, which depends on TMPRSS2-ERG for proliferation. TMPRSS2-ERG is generally regulated by androgen at the transcriptional level. Our finding reveals a new post-transcriptional mechanism of TMPRSS2-ERG regulation by Src and growth signals via miR-30 providing a rationale for targeting ERG-positive castration-resistant tumors with Src inhibitors.

Indexed as

AnimalsBlotting, WesternCell Line, TumorEpidermal Growth FactorEpithelial-Mesenchymal TransitionFluorescent Antibody TechniqueGenes, Tumor SuppressorHeterograftsHumansMaleMicroRNAsOligonucleotide Array Sequence AnalysisOncogene Proteins, FusionProstatic NeoplasmsProtein Kinase InhibitorsReal-Time Polymerase Chain ReactionEpidermal Growth FactorERG protein, humanMicroRNAsMIRN30b microRNA, humanOncogene Proteins, FusionProtein Kinase Inhibitorssrc-Family KinasesTMPRSS2-ERG fusion protein, humanTrans-ActivatorsTranscriptional Regulator ERG

Identifiers

PMID23728339
PMCPMC4370229
OpenAlexW1998605742

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.